Skip to main content
SpringerLink
Log in

Opioid Rotation in Clinical Practice

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Although chronic opioid therapy is usually initiated using short-acting opioids, many patients with chronic pain are subsequently converted to long-acting and extended-release preparations. In clinical practice, optimal management requires careful individualization of dosage in order to achieve an appropriate balance of efficacy and adverse effects. After successful initiation and stabilization of opioid treatment, subsequent changes in regimen may still be required to maintain efficacy with an acceptable adverse effect profile.

Methods

This is a qualitative review of the available literature from June 2012 or earlier on opioid rotation for the management of chronic pain in the clinical setting. The PubMed database was searched using various search terms, and additional articles were identified through manual search of the bibliographies of articles identified through the PubMed search. Papers were selected based on relevance to the topic.

Results

When considering opioid rotation, clinicians must take into account not only the significant differences in potency among opioid drugs but also the considerable interpatient variability in response to opioids. The estimate of relative potency used in calculating an appropriate starting dose when switching from one opioid to another has been codified on equianalgesic dose tables. To reduce the risk of unintentional overdose, a two-step calculation has been proposed, which incorporates an initial reduction (typically 25–50%) in the equianalgesic dose followed by a second evaluation based on the severity of pain at the time of rotation along with other medical or psychosocial factors that might alter the effectiveness and tolerability of the new drug. Given the uncertainty of accurately predicting a patient’s response to treatment, each initial exposure to a new opioid should be considered a discrete clinical trial to assess the degree of response. Systematic reviews of opioid rotation have documented the re-establishment of adequate pain control or reduced adverse effects in 50–80% of patients.

Conclusions

Although continued research is needed to refine equianalgesic doses further, opioid rotation is an important and necessary practice in patients with chronic cancer or noncancer pain that is refractory to the initially used opioid.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353:1695–1700.

    Article  PubMed  CAS  Google Scholar 

  2. Wilson KE. Psychological implications of chronic pain. In: Raj P, ed. Practical Management of Pain. 3rd edition. St. Louis, MO: Mosby Inc; 2000:316–332.

    Google Scholar 

  3. World Health Organization. Cancer pain relief, with a guide to opioid availability. WHO Guideline. 2nd edition. Geneva, Switzerland: WHO. 1996:13–15.

    Google Scholar 

  4. Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain. 2003;7:381–386.

    Article  PubMed  CAS  Google Scholar 

  5. Royal College of Anaesthetists, Royal College of General Practitioners, Royal College of Psychiatrists. Recommendations for the Appropriate Use of Opioids for Persistent Non-cancer Pain. London: The Pain Society; 2004. Available at: http://www.anaesthesiauk.com/documents/opioids_doc_2004.pdf. Accessed May 10 2012.

    Google Scholar 

  6. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–130.

    Article  PubMed  CAS  Google Scholar 

  7. Governale L. Outpatient Prescription Opioid Utilization in the US, Years 2000–2009. Presented July 22, 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM220950.pdf. Accessed May 10 2012.

  8. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11:S63–S88.

    PubMed  Google Scholar 

  9. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64:465–474.

    Article  CAS  Google Scholar 

  10. American Academy of Pain Medicine and the American Pain Society. The use of opioids for the treatment of chronic pain: a consensus statement. Clin J Pain. 1997;13:6–8.

    Article  Google Scholar 

  11. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57:1331–1346.

    Article  Google Scholar 

  12. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84:602–612.

    PubMed  CAS  Google Scholar 

  13. Carson S, Thakurta S, Low A, Smith B, Chou R. Drug Class Review: Long-Acting Opioid Analgesics: Final Update 6 Report. Portland, OR: Oregon Health and Science University; 2011.

    Google Scholar 

  14. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304–315.

    Article  PubMed  CAS  Google Scholar 

  15. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. 2000;90:933–937.

    Article  PubMed  CAS  Google Scholar 

  16. Grilo RM, Bertin P, Scotto di Fazano C, et al. Opioid rotation in the treatment of joint pain. A review of 67 cases. Joint Bone Spine. 2002;69:491–494.

    Article  PubMed  CAS  Google Scholar 

  17. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol. 2008;154:384–396.

    Article  PubMed  CAS  Google Scholar 

  18. Martini L, Whistler JL. The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol. 2007;17:556–564.

    Article  PubMed  CAS  Google Scholar 

  19. Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag. 2008;4:123–130.

    PubMed  Google Scholar 

  20. Fine PG. Clinical approaches to special issues related to opioid therapy. Semin Oncol Nursing. 2009;25:S20–S28.

    Article  Google Scholar 

  21. Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315–1321.

    Article  PubMed  CAS  Google Scholar 

  22. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2010;(11):CD004847.

  23. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009;25:2133–2150.

    Article  PubMed  CAS  Google Scholar 

  24. Muller-Busch HC, Lindena G, Tietze K, Woskanjan S. Opioid switch in palliative care, opioid choice by clinical need and opioid availability. Eur J Pain. 2005;9:571–579.

    Article  PubMed  CAS  Google Scholar 

  25. Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage. 2005;29:S2–S9.

    Article  PubMed  CAS  Google Scholar 

  26. Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol. 2002;66:285–306.

    Article  PubMed  CAS  Google Scholar 

  27. Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci. 1999;20:19–26.

    Article  PubMed  CAS  Google Scholar 

  28. Matthes HW, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the muopioid-receptor gene. Nature. 1996;383:819–823.

    Article  PubMed  CAS  Google Scholar 

  29. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci. 2001;22:67–70.

    Article  PubMed  CAS  Google Scholar 

  30. Kadiev E, Patel V, Rad P, et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol. 2008;4:77–91.

    Article  PubMed  CAS  Google Scholar 

  31. Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other p-opioid receptor agonist analgesics for management of terminal cancer pain case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer. 1993;72:2266–2272.

    Article  PubMed  CAS  Google Scholar 

  32. Chia YY, Chow LH, Hung CC, Liu K, Ger LP, Wang PN. Gender and pain upon movement are associated with the requirements for postoperative patient-controlled iv analgesia: a prospective survey of 2,298 Chinese patients. Can J Anaesth. 2002;49:249–255.

    Article  PubMed  Google Scholar 

  33. Sidebotham D, Dijkhuizen MRJ, Schug SA. The safety and utilization of patient-controlled anaesthesia. J Pain Symptom Manage. 1997;14:202–209.

    Article  PubMed  CAS  Google Scholar 

  34. De Kock M, Scholtes JL. Postoperative PCA in abdominal surgery. Analysis of 200 consecutive patients. Acta Anaesthesiol Belg. 1991;42:85–91.

    PubMed  Google Scholar 

  35. Niesters M, Dahan A, Kest B, et al. Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. Pain. 2010;151:61–68.

    Article  PubMed  Google Scholar 

  36. Miller PL, Ernst AA. Sex differences in analgesia: a randomized trial of mu versus kappa opioid agonists. South Med J. 2004;97:35–41.

    Article  PubMed  Google Scholar 

  37. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 2002;12:3–9.

    Article  PubMed  CAS  Google Scholar 

  38. Ross JR, Rutter D, Welsh K, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5:324–336.

    Article  PubMed  CAS  Google Scholar 

  39. Reyes-Gibby CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130:25–30.

    Article  PubMed  CAS  Google Scholar 

  40. Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-Omethyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005;116:73–78.

    Article  PubMed  CAS  Google Scholar 

  41. Ross JR, Riley J, Taegetmeyer AB, et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer. 2008;112:1390–1403.

    Article  PubMed  CAS  Google Scholar 

  42. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240–1243.

    Article  PubMed  CAS  Google Scholar 

  43. United States Food and Drug Administration. Approved Drug Products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed Jun 19 2012.

  44. Kadian (morphine sulfate extended-release) capsules CII [package insert]. Morristown, NJ: Actavis Kadian; 2010.

  45. Avinza (morphine sulfate extended-release capsules) CII [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2011.

  46. Cone EJ, Caplan YH, Moser F, Robert T, Black D. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J Anal Toxicol. 2008;32:319–323.

    PubMed  CAS  Google Scholar 

  47. OxyContin (oxycodone hydrochloride controlled-release) tablets CII [package insert]. Stamford, CT: Purdue Pharma LP; 2011.

  48. Opana ER (oxymorphone hydrochloride) extended-release tablets CII [package insert]. Chadds Ford, PA: Endo Pharmaceuticals; 2011.

  49. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004;57:287–297.

    Article  PubMed  CAS  Google Scholar 

  50. Exalgo (hydromorphone hydrochloride) extended-release tablets CII [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc.; 2010.

  51. Duragesic (fentanyl transdermal system) CII [package insert]. Raritan, NJ: PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009.

  52. Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther. 2001;298:1021–1032.

    PubMed  CAS  Google Scholar 

  53. Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1995;272:505–510.

    PubMed  CAS  Google Scholar 

  54. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11:S133–S153.

    PubMed  Google Scholar 

  55. Levorphanol tartrate tablets [package insert]. Columbus, OH: Roxane Laboratories, Inc.; 2011.

  56. Ultram ER (tramadol HCl) extended-release tablets [package insert]. Raritan, NJ: PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009.

  57. Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1998;28:1129–1165.

    Article  PubMed  CAS  Google Scholar 

  58. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980;17:102–105.

    Article  PubMed  CAS  Google Scholar 

  59. De Gregori M, Allegri M, De Gregori S, et al. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab. 2010;11:276–282.

    Article  PubMed  Google Scholar 

  60. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392:30–34.

    Article  PubMed  CAS  Google Scholar 

  61. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81:429–444.

    Article  PubMed  CAS  Google Scholar 

  62. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993;54:463–472.

    Article  PubMed  CAS  Google Scholar 

  63. Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43:983–1013.

    Article  PubMed  Google Scholar 

  64. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32:447–454.

    Article  PubMed  CAS  Google Scholar 

  65. Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1356–1358.

    Article  PubMed  CAS  Google Scholar 

  66. Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract. 2007;7:352–356.

    Article  PubMed  Google Scholar 

  67. Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138:507–513.

    Article  PubMed  Google Scholar 

  68. Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazor M; Canadian Palliative Care Clinical Trials Group. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. J Clin Oncol. 1996;14:1713–1717.

    PubMed  CAS  Google Scholar 

  69. De Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity in terminal cancer patients. J Pain Symptom Manage. 1995;10:378–384.

    Article  PubMed  Google Scholar 

  70. Lee MA, Leng MEF, Tiernan EJJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001;15:26–34.

    Article  PubMed  CAS  Google Scholar 

  71. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84:613–624.

    PubMed  CAS  Google Scholar 

  72. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38:426–439.

    Article  PubMed  CAS  Google Scholar 

  73. Houde RW, Wallenstein SL, Rogers A. Clinical pharmacology of analgesics. 1. A method of assaying analgesic effect. Clin Pharmacol Ther. 1960;1:163–174.

    PubMed  CAS  Google Scholar 

  74. Houde R, Wallenstein S, Beaver W. Evaluation of analgesics in patients with cancer pain. Clin Pharm. 1966;1:59–97.

    Google Scholar 

  75. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003;19:286–297.

    Article  PubMed  Google Scholar 

  76. Brant JM. Opioid equianalgesic conversion: the right dose. Clin J Oncol Nurs. 2001;5:163–165.

    PubMed  CAS  Google Scholar 

  77. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;78:852–857.

    Article  PubMed  CAS  Google Scholar 

  78. Fine PG, Portenoy RK; for the Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418–425.

    Article  PubMed  Google Scholar 

  79. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios of opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001;22:672–687.

    Article  PubMed  CAS  Google Scholar 

  80. Simpson KH. Individual choice of opioids and formulations: strategies to achieve the optimum for the patient. Clin Rheumatol. 2002;21:S5–S8.

    Article  PubMed  Google Scholar 

  81. McNicol E, Horowicz-Mehler N, Fisk RA, et al; American Pain Society. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;5:231–256.

    Google Scholar 

  82. Morita T, Takigawa C, Onishi H, et al; Japan Pain, Rehabilitation, Palliative Medicine, and Psycho-Oncology (PRPP) Study Group. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. J Pain Symptom Manage. 2005;30:96–103.

    Article  PubMed  CAS  Google Scholar 

  83. Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract. 2007;7:123–129.

    Article  PubMed  Google Scholar 

  84. Narabayashi M, Saijo Y, Takenoshita S, et al. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol. 2008;38:296–304.

    Article  PubMed  Google Scholar 

  85. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med. 2008;9:595–612.

    Article  PubMed  Google Scholar 

  86. US Food and Drug Administration. Information for Healthcare Professionals: Methadone Hydrochloride. Rockville, MD: United States Food and Drug Administration. 2006. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142841.htm. Accessed Aug 24 2012.

    Google Scholar 

  87. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999–2006. Hyattsville, MD: United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2009. NCHS databrief no. 2. Available at: http://www.cdc.gov/nchs/data/databriefs/db22.htm. Accessed May 10 2012.

    Google Scholar 

  88. Katz NP, Birnbaum HG, Castor A. Volume of prescription opioids used nonmedically in the United States. J Pain Palliat Care Pharmacother. 2010;24:141–144.

    Article  PubMed  Google Scholar 

  89. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152:85–92.

    PubMed  Google Scholar 

  90. US Department of Health and Human Services, US Food and Drug Administration. Prescription drug products containing acetaminophen; actions to reduce liver injury from unintentional overdose. Federal Register. 2011;76:2691–2697.

    Google Scholar 

  91. Gilson AM, Maurer MA, Joranson DE. State medical board members’ beliefs about pain, addiction, and diversion and abuse: a changing regulatory environment. J Pain. 2007;8:682–691.

    Article  PubMed  Google Scholar 

  92. Craig DS. The Food and Drug Administration risk evaluation and mitigation strategy. J Pain Palliat Care Pharmacother. 2010;24:145–148.

    Article  PubMed  Google Scholar 

  93. US Food and Drug Administration. FDA introduces new safety measures for extended-release and longacting opioid medications. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm. Accessed Jul 9 2012.

  94. Jacox A, Carr DB, Payne R. New clinical practice guidelines for the management of pain in patients with cancer. N Engl J Med. 1994;330:651–655.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. International Clinical Research Institute, 8675 College Boulevard, Suite 150, Overland Park, Kansas, 66210, USA

    Srinivas R. Nalamachu

Authors
  1. Srinivas R. Nalamachu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Srinivas R. Nalamachu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nalamachu, S.R. Opioid Rotation in Clinical Practice. Adv Therapy 29, 849–863 (2012). https://doi.org/10.1007/s12325-012-0051-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-012-0051-7

Keywords

Search

Navigation